Hyperprolactinemia in the mechanisms of uterine leiomyoma develop

Authors

  • Н. В. Косей SI «Institute of Pediatrics, Obstetrics and Gynecology, NAMS of Ukraine», Ukraine
  • Л. А. Васильченко Institute of Pediatrics, Obstetrics and Gynecology, NAMS of Ukraine, Ukraine
  • В. А. Джупин Institute of Pediatrics, Obstetrics and Gynecology, NAMS of Ukraine, Ukraine

DOI:

https://doi.org/10.18370/2309-4117.2013.13.99-112

Keywords:

uterine leiomyoma, prolactin, Cyclodynon

Abstract

The studies have shown that correction of hyperprolactinemia can be considered as a legitimate component of the complex pathogenetic treatment of uterine leiomyoma and the prevention of its growth. The main objective of treatment in cases of small size uterine leiomyoma is a stabilization of tumor size and preventing its rapid growth and normalization of hormonal status.

Herbal remedies with dopaminergic activity (in particular Cyclodynon) against antistress the rapy are an effective method of correction in patients with uterine leiomyoma and mild functional hyperprolactinemia.

Author Biographies

Н. В. Косей, SI «Institute of Pediatrics, Obstetrics and Gynecology, NAMS of Ukraine»

MD, Chief researcher at the Department of Endocrine Gynecology

Л. А. Васильченко, Institute of Pediatrics, Obstetrics and Gynecology, NAMS of Ukraine

graduate student

Department of Endocrine Gynecology

References

Bernichtein S, Touraine Ph, Goffin V New concepts in prolactin biology // Journal of Endocrinology. – 2010. – Vol. 206. – 1–11.

Egli M Prolactin secretion patterns: basic mechanisms and clinical implications for

reproduction / Egli M, Leeners B, Kruger T.H.C // Reproduction. – 2010. – Vol. 140. – P. 643–654.

Clapp C, Thebault S, Qeziorski MC Peptide hormone regulation of angiogenesis, Physiol Rev 89. – 2009. – P. 1177–1215.

Grattan DR Prolactine: A pleirotropicneuroendsocrine hormone // Qournal of Neuroendocrinology. – 2008. – Vol. 20. – P. 752–763.

Bole-Feysot C Prolactin and its receptor, actions, signal transduction pathways and

phenotypes, observedin PRL receptor knockout mice // Endoc Rev. – 1998. – Vol. 19. – P. 225.

Ben Jonathan N What can we learn from rodents about prolactin in humans? / Jonathan N, Ben C.R. Lapensee, Lapensee EW // Endocrine Reviews 29. – 2008. – P. 1–41.

Nowak RA, Mora S, Diehl T et al. Prolactin is an autocrine or paracrine growth factor for human myometrial and leiomyoma cells // Gynecol Obstet Invest. – 1999. – Vol. 48. – P. 127–132.

Bernichtein S New concepts in prolactin biology / Bernichtein S, Touraine P, Goffin V // Journal of Endocrinology. – 2010. – Vol. 206. – P. 1–11.

Stattin P Plasma prolactin and prostate cancer risk: a prospective study // International Journal of Cancer. – 2001. – Vol. 92. – P. 463–465.

Ginsburg E Prolactin synthesis and secretion by human breast cancer cells / Ginsburg E, Vonderhaar BK // Cancer Research. – 1995. – Vol. 55. – P. 2591–2595.

Levina V Biological Significance of Prolactin in Gynecologic Cancers / Levina V, Nolen B, 1 YunYun Su, Godwin A, Fishman D, Liu J //Cancer Res. – 2009. – 69: (12).

Goffin V, Struman I, Mainfroid V et al. 1994 Evidence for a second receptor binding site on human prolactin // Journal of Biological Chemistry. – 1994. – P. 32598–32606.

Baban RS Prolactin receptors in uterine leiomyomas. / Baban RS, Al-Zuheiri ST, Farid YY // Saudi Med J. – 2008. – Vol. 29, № 11. – P. 1593–1596.

Gellersen B Nonpituitary human prolactin gene transcription is independent of Pit-1 anddifferentially controlled in lymphocytes and in endometrial stroma / Gellersen B, Kempf R, Telgmann R, Di.Mattia GE // Molecular Endocrinology. – 1994. – Vol. 8. – P. 356–373.

Chapitis J, Riddick DH, Betz LM et al. Physicochemical characterization and functional activity of fibroid prolactin produced in cell culture // Am. J. Obstet. Gynecol. – 1988. – Vol. 158, № 4. – Р. 846–853.

Nowak RA, Rein MS, Heffen LJ et al. Production of prolactin by smooth muscle cells cultured from human uterine fibroid tumors // Clin. Endocrinol. Metab. – 1993. – Vol. 76, № 5. – P. 1308–1313.

Daly DC, Walters CA, Prior JC et al. Prolactin production from proliferative phase leiomyoma // Am. J Obstet. Gynecol. – 1984. – Vol. 148, № 8. – Р. 1059–1063.

Dixon D, Flake GP, Moore AB et al. Cell proliferation and apoptosis in human uterine leiomyomas and myometria // Virchows Arch. – 2002. – Vol. 441, № 1. – Р. 53–62.

Chapitis J, Riddick DH, Betz LM et al. Physicochemical characterization and functional activity of fibroid prolactin produced in cell culture // Am. J. Obstet. Gynecol. – 1988. – Vol. 158, № 4. – Р. 846–853.

Daly DC, Walters CA, Prior JC et al. Prolactin production from proliferative phase leiomyoma // Am. J Obstet. Gynecol. – 1984. – Vol. 148, № 8. – Р. 1059–1063.

Nowak RA, Mora S, Diehl T, Rhoades AR, Stewart EA Prolactin Is an Autocrine or Paracrine Growth Factor for Human Myometrial and Leiomyoma Cells // GynecolObstet Invest. – 1999. – Vol. 48. P. 127–132.

Melli MS Comparison of the effect of gonadotropin-releasing hormone analog (Diphereline) and Cabergoline (Dostinex) treatment on uterine myoma regression // Saudi Med J. – 2007. – Vol. 28 (3). – P. 445–450.

Sabry M Innovative Oral Treatments of Uterine Leiomyoma // Obstetrics and Gynecology International. – Volume 2012. – P. 1–10.

Sayyah-Melli M, Tehrani-Gadim S, Dastranj-Tabrizi A et al. Comparison of the effect of gonadotropin-releasing hormone agonist and dopamine receptor agonist on uterine myoma growth. Histologic, sonographic, and intra-operative changes // Saudi Medical Journal. – 2009. – Vol. 30, № 8. – P. 1024–1033.

Arkhipkina TL The role of prolactin in the formation of carbohydrate metabolism in patients with polycystic ovary syndrome // Problems of endocrine pathology. – 2010. – № 1. – Р. 38–44.

Tatarchuk TF Current approaches to diagnosis and treatment of hyperprolactinemia // Reproductive Endocrinology. – 2012. – № 1 (3). – P. 44.

Vikhlyaeva EM Guidelines for diagnostics and treatment of uterine leiomyoma. – Moscow: MEDpress-Inform, 2004. – 400 p.

Fakhrutdinova EH Reproductive health of women after conservative myomectomy: Dissertation for the degree of PhD. – M., 2004. – P. 20–27.

Torchinov AM, Umahanova MM, Boklagova YV Investigation of the hormonal profile in patients after gynecological surgery // Obstetrics and Gynecology: Scientific and Practical Journal. – 2012. – № 1. – P. 80–87.

Piddubniy MI, Khaskhanova LH, Dukhin AO et al. Long-term results reproductive health of women after conservative myomectomy // Bulletin of the Russian Peoples’ Friendship University. – 2002. – № 1. – P. 125–128.

Burdina II The possibilities of herbal medicine in the treatment of benign breast disease // Reproductive Health. – 2005. – № 2 (22). – P. 131–133.

Cossey NV Phytotherapy in treatment of dishormonalbenign breast diseases in women with uterine leiomyomas // Reproductive Women Health. – 2008. – № 4. – P. 171–173.

Published

2013-11-17

How to Cite

Косей, Н. В., Васильченко, Л. А., & Джупин, В. А. (2013). Hyperprolactinemia in the mechanisms of uterine leiomyoma develop. REPRODUCTIVE ENDOCRINOLOGY, (13), 99–112. https://doi.org/10.18370/2309-4117.2013.13.99-112

Issue

Section

Clinical case

Most read articles by the same author(s)

1 2 3 4 > >>